Dianhydrogalactitol

Drug Overview

Dianhydrogalactitol is a specialized chemotherapy medication being developed to treat difficult-to-reach tumors, particularly those in the brain. It is classified as a “next-generation” alkylating agent. Unlike many traditional cancer drugs, it is specifically designed to cross the blood-brain barrier, which is a protective shield that keeps most medicines from entering the brain.

Here are the key details about this agent:

• Generic Name: Dianhydrogalactitol (also known as VAL-083).
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: Bi-functional Alkylating Agent / DNA-targeting therapy.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. It has received “Orphan Drug” and “Fast Track” designations from the FDA for specific brain cancers, but it is not yet approved for general public use.

What Is It and How Does It Work? (Mechanism of Action)

Dianhydrogalactitol is a “Smart Targeting” chemotherapy. To understand how it works, think of a cancer cell’s DNA as a set of instructions. If you can damage those instructions, the cell cannot grow or copy itself.

Targeting the DNA

Most chemotherapy drugs struggle to enter the brain because they are too large or have the wrong chemical charge. Dianhydrogalactitol is small and fat-soluble, which allows it to slip through the blood-brain barrier easily. Once inside the cancer cell, it looks for the DNA.

The Molecular “Staple”

At the molecular level, dianhydrogalactitol creates a permanent chemical bond at a specific spot on the DNA strand called the N7 position of guanine. It acts like a “staple” that binds two parts of the DNA together. This is called DNA cross-linking.

Bypassing Resistance

Many brain tumors, like Glioblastoma, produce a protein called MGMT. This protein acts like a repair crew that fixes DNA damage caused by standard chemotherapies. Dianhydrogalactitol is unique because it damages the DNA in a way that the MGMT repair crew cannot fix. This makes it a powerful option for patients whose tumors have become resistant to standard treatments.

FDA Approved Clinical Indications

Because dianhydrogalactitol is an investigational agent, it does not yet have official FDA-approved indications for routine use. However, it is being tested in clinical trials for the following:

Oncological Uses (In Clinical Trials):

• Glioblastoma Multiforme (GBM): Specifically for patients whose tumors have the MGMT protein or whose cancer has returned after standard therapy.
• Ovarian Cancer: Used for patients who no longer respond to platinum-based chemotherapy.
• Pediatric Brain Tumors: Investigated for use in children with high-grade gliomas or medulloblastoma.

Non-oncological Uses:

• There are currently no non-cancer uses for this drug.

Dosage and Administration Protocols

Dianhydrogalactitol is given as an infusion into a vein. Because it is an investigational drug, the exact dose is often tailored to the specific clinical trial protocol and the patient’s body size.

Clinical Efficacy and Research Results

Clinical studies conducted between 2020 and 2026 have shown promising results for patients with limited treatment options.

Survival in Glioblastoma

In Phase 2 clinical trials, dianhydrogalactitol has been studied in patients with recurrent brain tumors. Data suggests a Median Overall Survival (mOS) of approximately 8 to 10 months in patients who had already failed standard therapy. This is considered significant for recurrent GBM.

Disease Progression

Research shows that the drug can lead to a “Disease Control Rate” (the percentage of patients whose tumors shrink or stop growing) of over 40% in certain resistant brain cancer populations. In ovarian cancer trials, the drug has shown activity in cells that were previously resistant to every other known chemotherapy.

Safety Profile and Side Effects

Dianhydrogalactitol is generally better tolerated than many older chemotherapies because it targets the DNA more specifically.

Common Side Effects (>10%):

• Myelosuppression: A temporary drop in blood cell counts (white cells, red cells, and platelets).
• Nausea: Mild to moderate stomach upset, usually manageable with standard anti-nausea medicine.
• Fatigue: A general feeling of tiredness or low energy.

Serious Adverse Events:

• Severe Thrombocytopenia: A very low platelet count that increases the risk of bruising or bleeding.
• Infection Risk: Low white blood cell counts can make it easier to get sick.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

• Blood Monitoring: Patients must have their blood counts checked weekly. If platelets fall too low, the next dose is delayed.
• Hydration: Drinking plenty of fluids helps the body process the medication through the kidneys.

Research Areas

Dianhydrogalactitol is currently a focus in “Precision Immunotherapy” and “Regenerative Medicine” research. Scientists are exploring how this drug can be combined with immunotherapy (like PD-1 inhibitors). Because dianhydrogalactitol kills cancer cells in a way that releases “alarm signals,” it may help the immune system recognize and attack the remaining tumor.

In regenerative medicine research, doctors are looking at ways to use stem cell “rescue” (storing a patient’s own bone marrow cells) to allow for higher doses of the drug without permanently damaging the patient’s ability to make new blood cells.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Complete Blood Count (CBC): To ensure baseline blood levels are safe for chemotherapy.
• MGMT Testing: A genetic test on the tumor tissue to see if the cancer is likely to be resistant to other standard drugs.

Precautions During Treatment:

• Monitor for Fever: Any temperature over 38°C must be reported to the doctor immediately.
• Avoid Injury: Because platelets may be low, use a soft toothbrush and avoid activities that could cause bruising.

“Do’s and Don’ts” List:

• DO keep all appointments for blood tests; these are vital for your safety.
• DO eat small, frequent meals if you feel nauseous.
• DON’T take any new supplements or herbal medicines without asking your oncologist first.
• DON’T ignore sudden headaches or changes in vision.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Dianhydrogalactitol is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.